DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine

Exclusion Criteria

• •\* Patient has had a transplant prior to sample collection
• •* Patient has had Androgen (e.g. Flutamide, Androcur, Casodex, Nilandron) or Luteinizing hormone-releasing hormone (LHRH) (e.g. Lupron, Zoladex) therapy
• •* Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection
• •* Patient has chronic indwelling urinary catheter
• •* Patient has had a urinary tract infection within the 14 days prior to sample collection
• •* Patient has immunotherapy (e.g. Kwon study drugs) for prostate cancer prior to sample collection
• •* Patient has a history of bladder cancer
• •* Patient has had a biopsy within the last 6 weeks (excluding non-melanoma skin biopsies) of sample collection
• •* Patient has had surgery to completely remove current target pathology prior to sample collection
• •* Patient has a prior history of prostate carcinoma/adenocarcinoma
• •* Patient has received chemotherapy class drugs (e.g. Docetaxel, Methotrexate) within the 5 years prior to sample collection
• •* Patient has received therapeutic radiation prior to sample collection
• •* Patient has had focal ablation \[e.g. High-intensity focused ultrasound (HIFU) or cryoablation\] of prostate cancer prior to sample collection
• •* Patient has known primary cancer outside of the prostate within the last 5 years (not including basal cell or squamous cell skin cancers) of sample collection